MEMPHIS, Tenn. (WMC) -A new study finds that xAI’s operations could factor into air pollution and health damages in areas of the Mid-South. The Southern Environmental Law Center conducted an ...
Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China. Kailera Therapeutics and Hengrui Pharma have claimed mid-stage victory for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results